CPhI is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Informa

Trend report

2024 Outsourcing Forecast report

Global CDMO Trends: the 2024 outsourcing forecast

Pharmaceutical outsourcing strategies have evolved to match the dynamic needs of drugmakers and biotechs. As more and more pharmaceutical companies outsource some percentage of their operations, the partnerships between contracted organisations and drug sponsors are shifting in response to changing priorities from both parties. 

The future of pharmaceutical outsourcing is constantly changing, and success will depend on the pharma industry’s ability to adapt and evolve to meet these challenges.

Some of our report contributors
With thanks to our contributors for their time and expertise
Peter Bigelow
xCell Strategic Consulting
President
Stephanie Gaulding
Pharmatech Associates
Managing Director
Anil Kane
Thermo Fisher Scientific
Executive Director, Global Head of Technical & Scientific Affairs
Bikash Chatterjee
Pharmatech Associates
President, Chief Science Officer

This comprehensive report covers:

  • End-to-end services and integrated capabilities 
  • Global portfolios and operations for access to the right expertise and patients 
  • Development, manufacturing, and research capabilities for advanced therapeutics 
  • Global regulatory knowledge and considerations 
  • Diversification of supply chain activities 
     

From manufacturing post-COVID-19 to the boom in the weight-loss drug market, the dynamism of the pharmaceutical market has never been more apparent. Our latest Trend Report explores the evolving landscape of pharmaceutical outsourcing, and how strategies for both drug sponsors and vendors are changing to meet the demands of a different world.

RM3 ImageRM3 Image - 9